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Abstract
9/c surveyed 652 HavaL phi s,cians who diagnosed nepatitis C
(HOt’) since 1995 Less than 200 of ircensed physrcans have
diagnosed HCV and initial estimates suggest There are 12000 to
18.000 undiagnosed HCV cases in Hawaii, Treatment is concen
trated among twelve physicians and aggressive case finding may
oervheln7pmsentresources More onmary care phys,cians neeo
to oarricrpate in the detection management of HCV
Introduction
Hepatitis C virus HCV) is the most common cause of liver failure
and liver transplants in the Jinited States. Nationally. HCV causes
about 70c of chronic liver disease, an illness responsible for 10.000
tatalities annuallvH The CS prevalence is estimated to be between
1.4% and I .8% and two thirds of cases are asymptomatic. This
incidence applied to Hawaii would mean that between 16,000 and
21.000 persons are HCV positive. At the completion of this study in
March of 2000. se have identified 3.600 HCV cases with possibly
another I 2.000 to I 8.000 persons not aware they are infected. OOen
HCV infected persons are unaware of the risk factors or the need to
be tested.
Due to the insidious nature of HCV infection, initial diagnosis
depends on a high index of suspicion. Knowledge of this disease has
expanded rapidly o’. er the last few ears .and diagnostic procedures
and recommendations for treatment are changing. Treatment is
prolonged, has significant adverse effects, has less than a 50%
success rate and decisions to initiate or continue antiviral therapy
can be a challenge to medical judgment. The potential frequenc of
this disease in Has au’s population could overwhelm the services
provided by local Gastroenterolosists and Hepatologists (GI). Much
of’ the burden of care may fall on family practitioners (FP) and
internists IM) and it is important they remain current in the
ramifications of HCV.
Everhirt et. al.- reported on a nai ional questionnaire to
Hepatologists and Gastroenterolosists on the management of HCV,
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[sing their sun ey. forwarded to us by Dr. Hoofnagle. we developed
ourown questionnaire (appendix I ) and assessed physician manage
ment of HCV from those who had made that diagnosis since the
beginning of mandatory reporting. Physicians were questioned on
advice to patients and the management of two hypothetical cases.
Materials and Methods
Since October 1997, all laboratories in Hawaii have reported all
positive tests for HCV to the Hepatitis Control Section, Epidemiol
ogy Branch, Hawaii Department of Health. We identified all physi
cians who have diagnosed at least one case of HCV infection. We
mailed our questionnaire to 652 physicians. The mail—out included.
as an incentive to respond. the NIH National Consensus Statement.
Management of Hepatitis C.3 Physicians were asked to answer the
questions as they applied to their own practice and not refer to the
NIH statement until after the’ answered the questionnaire. Jo
maintain anonymity we destroyed identifiers to the questionnaires.
We made a second contact by telephone to non-responders, faxed a
second survey and asked them to fax us their completed response. Of
the remaining who still did not respond, we sent a second mail out
with a Coppertone gift certificate of ten dollars. This last effort
generated about 35 more surveys. Initial response to the first mail
out was about 250 while total responders to all three contacts
numbered 314 (48%). We analyzed the data by comparison of
proportions in EPI INFO 6.04b, 1999, and results were considered
significant at alpha 0. 05. Discrepancies in total numbers reported
on specil’ic survey questions were due to some responders returning
incomplete surve s. The Department of Health (DOH) institutional
Review Board approved the study design.
Results
Of the 3 14 responders almost 800 reported their specialti as
internal niedicine. family/general practitioner or gastroenterologv/
hepatology, When compared to our registry of 3,362 practicing
physicians in Hawaii, our study group was weighted toward the
above specialties. During the study sear. 86 of respondents
reported they saw fewer than I (I HCV patients and 140 saw more
than 10 patients. Of GI, 750 reported seeing more than (1 patients.
Over 750- of respondents referred their patients once they made the
diagnosis. Most GI (96%) did not refer their patients and 10 of the
1 2 physicians who treat more than ten patients per year were GI. IM
and FP showed a similar distribution to non—(il in all stirs ey
responses.
More GI than the other Hass au phy sicians inon—Gl ) reported
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increased restrictions in case management from their patient’s
managed care or insurance compan\ (67% vs .38 p .005). The
same was true when grouping ph sicians by experience .Sixt —three
percent of the 44 physicians. I 8 (H and 26 non—GI. who saw more
than 10 patients in the past ‘ear reported increased restrictions while
38% of 231 ph sic ians who saw I to 1(3 patients in the past ear
reported increased difticulties P .0005
Comparing the general management of patients ) ‘Table I j. the
questionnaire prompted physicians to answer almost always”,
“sometimes” or “almost never” to the specific management ques
tions. Significant differences were that the GI group did not recom
mend condoms in monogamous sex as often as non-GI (21% vs.
59%, p < .001) and recommended hepatitis A and B immunizations
more frequently (83% vs. 57%, P = .01) and (88% vs. 66%. p = .02),
There were no other significant differences in the suggested man
agement questions
In Case I A 36 year old woman with positive antibody for I—ICV.
no risk factors and normal liver en,vmes. Table 2). most phvs icians
would confirm the diagnosis with antibody tests RIB1\
. or quali
tative antigen identification )PCR). There was an inverse relation
ship between 01 and non—GI with the use of RIBA or qualitative
PCR. More 01 would use the qualitative PCR (P = 0.01) while more
non-GI preferred the RIBA P = 0.001). lmporiantlv most of the
study group seemed to understand that in this case the positive EIA
should be confirmed. For all other responses there were no signifi
cant differences.
If HCV infection were confirmed 65% of GI and 57% of non-GI
would do or consider a liver biopsy. Fifty-eight percent of GI and
71%. of non—GI would do or consider quantitative PCR and about
one—third of both groups would do or consider an HCV genotype.
These tests are normall done only if treatment is considered, vet no
GI marked “yes” to treatment of this patient with imerferon. How—
ever. 50 would consider it. Forty—six percent of non-GI would do
or consider treatment and many physicians marked plus Rihavirin.
About 70 of both groups would do or consider ultrasound of the
abdomen, a test for extensive fibrosis or hepatic cell carcinoma
(HCC) and about 60% of both groups would consider liver biopsy.
Over 90% of both groups would follow this patient with serial liver
enzyme studies and 25% of GI and 20% of non-Gl would reassure
Physician Group Gl* % Non- P value
GI %
Not share toothbrush or razor 92 75 ns
Not share drinking glass 8 23 ns
Not hug or kiss a child 0 5 ns
Not donate blood or organs 91 85 ns
Minimize drinking alcohol 92 90 ns
Abstain from alcohol 96 79 ns
21 59 <.001
pçxartn,,_,, 75 86 ns
ha,__ 83 57 0.01
Vaccinate hepatitis b
— 88 66 0.03
Use herbal/alt, remedies 8 9 ns
and counsel only. There is an overlap on these latter two responses
which may reflect a limitation of the survey and an inconsistent
understanding of “counsel.’
Response Yes % Maybe No % * value
%
Physician GI All GI All GI All
—
Anti HCV 23 58 9 15 68 27 .001
Genotype 9 16 26 18 65 66 ns
Qualitative 57 28 17 19 26 58 .004
PCR
Quantitative 38 49 21 22 42 29 ns
PCR
If HCV is
confirmed
Liver biopsy 17 27 48 31 35 42 ns
Ultrasound 54 52 17 17 29 31 ns
of abdomen
ALTevery6- 92 91 0 5 8 4 ns
12 mo.
Counseling 25 20 21 22 54 59 ns
only
Antiviral Rx 0 16 50 40 50 44 ns
Response Yes % Maybe No % * value
%
Physician GI All GI All GI All
Group
Anti HCV 8 52 0 11 92 37 <.0001
Genotype 54 41 33 22 13 37 .02
Qualitative 21 30 0 17 79 53 01
PCR
Quantitative 79 76 13 10 8 14 ns
PCR
If HCV is
confirmed
Liver biopsy 50 76 33 18 17 8 .007
Ultrasound 92 82 4 9 4 10 ns
of abdomen
ALTevery6- 48 87 13 5 39 8 <.0001
12 mo.
Counseling 0 9 26 11 74 80 ns
Antiviral Rx 92 82 8 10 0 9 ns
Table 2: Management of Case 1 (A 36 yo woman with a
positive HCV antibody screen, normal liver enzymes and
no risk factors): Compare GI to all other Hawaii Physicians
(All = all responders less GI)
* Calculated as comparison of proportions tor yes answers
Table 3: Management of Case II 9A 54 yo man with positive
antibody, a history of blood transfusions, intermittent fatigue
and elevated liver enzymes): Compare GI to all other
Hawaii physicians (all = all responders less GI)
Table 1: Patient Ufestyle Recommendations:
Compare Hawaii Gastroenterolosists to all other reporting
Physicians (Almost Always responses).
• Physicians who identify themselves as Hepatologists or
Gastroenterolosists Calculated as comparison of proportions for yes answers
149
In Case 2 (A 54 year old man with positive antibody, a history of
blood transfusions, intermittent fatigue and ele ated liver enzymes,
Table 3). most CI would not confirm the diagnosis with a RIBA\ or
quahtative PCR but would go directly to a quantitanve PCR. Fili —
two—percent of non—Cl would do a RIBA. 30% would do a qualita—
nyc PCR and almost 80% would do a quantitative PCR, In this case
confirmation of the EIA is not necessary and it is best to go directly
to evaluanon %r treatment. Almost Q0” of CI and more than 6(Y’
of non—Cl would do or consider a genotype and almost 90Cc of non—
(ii would do or ccnsider a quantitative PCR. Most of both groups
(>80%) would do or consider liver biopsy, however. Cl are more
reluctant to mark a definitive yes (76% vs. 50%. P = .007). Most of
both groups would do ultrasound of the abdomen. A higher percent
age ofGI than non—Cl would not follow with senal ALTs (3 vs.
8%. P < .00(11. Most of both groups would not follow this paticnt
with counseling unIv and would treat this patient with Interferon and
Ri bavi rin.
Discussion
The respondents are heavily weighted toward family practice.
internal medicine and gastroenterology and arc not representative of
all Hawaii physicians. Due to the anonymous nature of the study, we
could not identify the specialties of the original 652 to whom we sent
survey forms: the respondents are compared to the total population
of licensed physicians in the state. Twenty-four of twent -five
(jastroenterolosists returned the surv cv hut only 24% oflM and 30%
of FP returned the survey. The respondents most I ikelv represented
those who are most knowledgeable about HCV. Since we have
identified only 3600 cases in a population that ma contain up to
2 I .000 at the time this stud\ was completed. there are likely a
number of phy sicians who are not looking for HCV infection, It is
possible that we overestimated prevalence. Fischer et. al.4 reported
a prevalence of 0.8%, screening for hepatitis C in a health mainte
nance organization and quoted other studies reporting a prevalence
lower than the national average. 1-lowever preliminary data from an
ongoing HCV survey of Hawaii citizens suggests a local prevalence
of 1.6%.
Of all the respondents. most refer their patients. and treatment is
concentrated among fewer than half of the Gastroenterolosist. If
there are truE 21 .000 cases in our population this group cannot do
all of the care. Seer reports that only 15—20% of those with chronic
HCV develop cirrhosis and/or hepatitic cell carcinoma. Recent
studies trom Germany Hn iatrogenieallv infectcd \somcn and from
Baltimore7in injection drug users show low risk of progression to
cirrhosis. Ho\k ever other studies suggest that approximately one—
third of patients will progress to cirrhosis h\ twenty x ears and
another th nd e ill have cirrhosis h thirty years. HCV patients need
long term foIIus up and although Gastroenterolosists max need to
e\ aluate and stage their disease, due to patient \ olume. primar\ care
ph sicians ma\ have to do much of the v ork. Much of the follow—
up and patient education can be done in conjunction with ph\ cician
sponsored support groups. Many patients need support groups to
overcome their guilt and/or anger, and to verify outside information
sources, such as the Internet. Also some patients on treatment suffer
serious psychological side effects and physician monitored support
eroups can more easily identify these effects in their carE ciagec.
PresentI
. there are several support itroups in Has an.
Gastroenterolosists and other physicians who see more than ten
HCV patients per year report more difficulty with restrictions from
managed care organizations. Those \kho have the most expertise
prohahl have more encounters with the managed (are organiza
tions and request more expensive procedures. Indications for appro
priate follow up and treatment are not clearly defined in all cases and
managed care oreani/atlons ma have difficulty defining v hat iS
appropriate treatment and follow up. However managed care orga
nizations should know s ho are truE kno ledgeable in the field,
Eight-three percent ofGl “almost always” recommend Hepatitis
A immunization and 79% “almost alwa s” recommend Hepatitis B
immuni/ation, while 57% of non-Cl “almost always” recommend
Hepatitis A and 66% “almost always” recommend Hepatitis B. This
difference is significant i Table I ). Patients ith chronic hepatitis are
nmre susceptible to severe disease if infected with other forms of
hepatitis “ and all FICV positive patients should be immunized
against Hepatitis A and 13.
Most l-lawaii Physicians agree that materials that might harbor
blood should not he shared with indi iduals with F-ICy. Open
wounds should be covered and bloody articles from the HCV
positive person should be disposed using universal precaution
techniques. Patients and their families need some basic instructions
in these techniques. Most respondents also agree that casual contacts
such as common chinaware ortouching another (kiss a child) do not
pose an\ real risk.
Though most respondents (83% would test the sexual partners of
HCV patients. there is a significant difference between (II and non—
Cl recommending condoms in monogamous relationships 21 % Cl
and 59% non—GD. Risk of sexual transmission of HCV is not well
defined. ST[) clinic attendees have a higher prevalence than the
general population but lower than IV drug users.’° Cross sectional
studies from Northern Europe and the US show a low incidence in
partners of index cases. Southern Europe and Asia report higher
incidences. however it seems that the risk of transmission in mo
nogamous discordant couples is low .‘ The quest ion becomes, is
having multipIe sexual partners a cause of transmission, a en n-
founder or an unrelated association? The NIH Consensus states that
there is insufficient data to recommend changes in the sexual
practices of monogamous partners.
The NIH recommends that drinking alcohol is a contraindication
to interleron therapy .A number of studies demonstrate the delete
rious effect ofdrinking alcohol in patients with chronic HCV.’
These effects include a more rapid progression to fibrosis and
hepatic cell carcinoma. Belientani et al5 report that alcohol con
sumption of greater than 30 grams/day significantly ageravates the
natural course of HCV and Loeuercio ci. al. sho the abstainer’
respond better to interferon treatment and have lots er HCV RN7\
levels than those s ho drink less than —If) grams of alcohol per day
Ho’s e er the adverse effect of’ small doses of alcohol are not
univ ersall\ accepted and recommendations vary from aIlos mug an
occasional drink7to total abstinence. ‘ ‘ Of Hawaii physicians.
96% of UI and 79% of non-Cl recommend total abstinence, Mem
bers of the St. Francis Hepatitis C patient support group strongly
recommend total abstinence and presently this is the wisest course,
Although third generation enzyme linked immunosorhani assays
EIA-3 ) arc more specific than theirpredecessors. false positives are
present among lots risk patients or blood donors A positive
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RIBA demonstrates the presence of antibodies hut does not confirm
viremia. Usually a negative RIBA indicates a false positive ETA. In
Case Table 2). 23% of the CI and 6X of non—GI would do RIBA
P <.0001) while 57% of CI and 2% of non—Cl (((lId do qualitative
PCR { P .004. The difference bet\\ cen the 2 eroups is significant
and reciprocal. In Case I. the EIr\ needs to bc confirmed h either
a RIBr\ or qualitative PCR. The qualitative PCR is more expensive
than the R IRA by several hundred dollars but does answer if the
patiem is S iremic or not. RIB-\ merck conOrms the presence of anti
HCV antibodies.
The NIH Consensus does not consider genot\ pine as part of the
routine management ot patients. Genetic variants respond dOter—
eml to therapy and genot ping predicts resp nse rate and treatment
duration. Treatment of patients \s ith genotype 1 requires a longer
duration. The position of the NIH Consensus is that there is no
rationale br treatment of patients ss ith normal aminotransferase
levels: therefore there is no need Lw genotyping in the routine
treatment ol Case I. Only a small percentage of our study group
would order this test (9% CI and 16% non-Cl).
There is little or no correlation between HCV-RNA titers and
disease severity and progression. Current quantitative assays are not
as sensitive as the qualitative PCR’. however, low titers are corre
lated with a better response to treattnent. The NIH Consensus
states that treatment of patients with persistently normal ALT levels
is not hcnebcial and may actLiallv induce Ii er enz\ inc abnormali
ties. We can inter from the NIH Consensus that the quantitatis e test
is not indicated. Yet over a third of the CI and almost half of non—Cl
would order this test and. in light of more recent studies, some
patients like Case I might benefit from treatment. Therefore Case I
could require genotype and qnantitatt\ e PCR testing.
The NI H Consensus does not give clear indications for liver
hiops\ in i-ICY patients. Histologic comparison of liver biopsies in
patients with normal or elevated A LTs can show similar degrees of
injur\ ‘ Patients with normal AITs tend lo have milder degrees of
hepatic injury but 14% still progress to fibrosisH Dienes et. al* also
report that significant fibrosis oeenrs in some HCV patients with
persistently normal ALT levels and normal serial ACTs or even a
negative PCR cannot absolutely predict the absence of fibrosis.
Those who have HCV with normal ALTs tend to he female and those
persons who contract the disease after 40 or 50 years of age tend to
have a more rapid progression. It would seem that the only way to
document progress ion or non—progression in all I—ICY patients is h
serial liver biopsies. This procedure does have risks, however, if
there is progression of disease, it ina be best to treat these patients
in spite of the NIH recommendations Studies of treatment of the’c
patients are currently unclersv a. - [H by percent of Cl would con
-
sidcr the possibility ot treatment and 5(L ol non-Cl would do or
consider treatment in this ptieiit Tvs ent\ -tive percent of the CI and
20’ of non—Cl would counsel onl\ . howes er it is better to continue
vvuh follow up of all HCV positis e patients.
In (ase 2 Table 3 there is little need to do RI BA eortfirmatioi.
In high—risk popuCitions the ‘enstims tt\ ot the E1ISA—3 is ereater
than OtY . As this gatietit is ltkel to he a candidate for treatment.
the qnulttativ e PCR test will confirm actix e in%ctton anu a
dl indicate the duration of treatment. (dttantitative PC’R sO
confirms viremia and indicates treatment prognosis hut is not as
sc nsitiv c is thc qu ilitattv c. tcst 01 Cil mIs vvould do a RIB A nid
only 21% would do a qualitati\ e PCR, Seventy-nine percent of CI
ss ould do a quantitative PCR and 54% would do a genotype. Fifty—
tvv o percent of non-Cl woLild do a RI BA and the difference betsy een
non—Cl and CI is hiehlc sigm ficant P < 0001
.
Thirt\ percent of
non—Cd would do a qual ltati\ e PCR and 7(* or non—Cl would also
do a qLianmitative PCR. It seems that physicians prefer a quantitative
PC’R in this patient. probabi as a cost saving measure.
Interestingly. only 50% of the CI would definitely do a liver
biopsy while 7%, of the non—Cl would do so However, another
third of Cl would consider liver biopsy. Liver biopsy is the onl
definttive method of deterntinine the presence of bibros is and the
imperative for reatmnent. 1 he more cautious approach of CI vs ith
Its er biopsy mar he a result ut more personal e\periences vs ith
complications.
Ninety—two percent of CI and 82% of the non—Cl vs ould do
ultrasound of the abdomen, There is a difference in opinion about
monitoring with serial ALTs bertveen CI and non—Cl (48% vs. 87%,
P < .0000. HCV liver disease can progress even when the patient
demonstrates repeated normal ALTs. Although less invasive, serial
-\LTs do not seem to he a completely satisfactory means to monitor
these patients hut the only alternative is serial liver biopsies. Most
Hawaii physicians would not he content with counseling only. but
vs ould treat case 2 with Interleron amid Rihavirin, This combination
therapy is now the standard for treatment
There is contusion among sonic Hawaii physicians about the
management of these cases. Somne of the discrepancies are due to the
Ii mits of the questionnaire hut some are due to mcomplete knowl
edge of I-ICY diagnosis and management, Another soum’ce of cont u—
sioti is the new information that challenges the position of the NI H
recomtnendations*’ Brmsr ph\ sicians who see only a fess HCV
ptents vvottld feeI the pressttre to update therttselves or present
cases rather than the data on HCV unless ther encountered a mew
HC\’ case. In Case 1 it vvould seem best to establish if this patient is
virernic, If the test is positive. thcti consider liver biopsy and mfthere
is liver damage, then eonstder treatment, The definitive factor is
progressive liver disease rather than abnormal ALTs as the NIH
recommendations suggest. If treatment is an option then quantita
tive PCR and genotyping are indicated. In Case 2 it would seem
more efficient to go right to quantitative testing, genotype and liver
biopsy.
We compared our non—Cl results to the National Survey of
GastroenteroIogists (NS Cl) cl mc three to four years prior to this
study and before the des elopment of the NIH recommendations
Tables 4 & 5). These responses t’eflect both the Hawaii Family
Praettcc and Internal Medicine responses. TahIe4 shows the Hays ad
noim-CI recotiimend Hepatitis A & B aecinaton more frequentir
[her have a ereater concetn ahotit the effects of alcohol amid sexual
transmission than does the \S CI surs eyed 4 yeats prey iolts)s. The
Flaw au eroup also has a beper ni’asp of the value of genotr pe and
anantitatiye PCR testnie, especiallr in Case 2
[he responders to’ this snr\ cc are not representative of Hays
mcans hut represent thase vs ho arc most aware and tn cst
interested in I-IC\ disease. It likely that a number of phasicians in
pnima7 care settmns’s are nt looking tor the disease. and diaenos:s
and treatment of 1-ICV are concentrated among a small eroup ‘dust
treatment is concentrated anlona’ 1)) Gastroenterologists and the
potentially large number of cases in the community could os er
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Table 4: Patient Lifestyle Recommendations:
Compare Hawaii non-Gl to National Survey2 results
(Almost Always responses).
Physician Group non- NS*
Gl% %
Not share toothbrush or razor 75 81
Ne drinkin lass 23
yorkischild 52
mizedn alcohol 90
Abstain from alcohol 79 33
Use condoms in mono. Sex 39 30
Chpn 86 54
nate he atitis A 570
66 32
* National Survey Gastroenterolosists
Table 5: Management of Cases 1 & 2,
Compare Hawaii non-GI to NS Gl (Yes answers).
Case 1 Case 2
fydaqp non-GI GI non-Gl NSc I
0/ % % %
Anti HCV 58 61 52 45
jcyote 5 41 13
Qualitative PCR 28 49 30 52
,
Quantitative PCR 49
jbipy
Ultrasound
17
27
52
-ALT6-l2mo.
76
45
32
33
91
76
82
78
91
64
5787
whelm present treatment resources. Much of the follow-up could he
done throuu”h ph\ ‘ician-sponsored support groups and primary
care/iamilv practice physicians are yr eli suited for this.
HCV is under—reported and there sac lear need to del clop and
publish guidelines br HQ\’ screenine. Risk factors that should alert
physicians include: blood or blood product transfusions before
1993. drug and alcohol abuse especially when ii involves IV drugs.
multiple sexual partners. tattoos done non-proiessionall. and ho
mnosexual male sex.
The 5 Il-I \ational Consensus Statement’ and update does not
address oil1 the issues and i’ in pai’t outdated. There are di tierences
of opinions in patient management among experts familiar with
these patients. Diagnostic tests are improved and have helped to
more easily identibv patients and predict treatment outcome. indica
nons br treatment are changmnc and there is frank disagreement with
the position of the ‘ lH Consensus Statement on the treattnent ol
patients aith normal ALT. \ianatned care oreaitizations that do
i o u tsc itiidmn. it dentits ht,h i isk p mantIs i at Is
intervention and promote support groups for these patients may
rednec treatmen.t coi.;ts i.n. th.e long run. •Patient support a.nd education.
in groups can he more effective and cheaper than tine-on-one patient
education in the phsicians office. Hos :tii Ph sicians scent to he
(Irate -cantons about liverbirrpso in these patients when compared to
NfS (ii. Present inbormation sugeest” that all patients oliaunosed
should be considered fbr un er hmopso - Periodic educational updates
to increaite• index of suspicion, especially for pt-ima y care phvi.-i
cians who see occasional FICV pati.enrs, are ei-se.n.tjal,
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State of Hawaii Department of Health
Hepatitis C Physician Survey
Please blacken your responses using a lead pencil or a black ballpoint pen. Thank You.
1. What is your medical specialty? (check all that apply)
Emergency Medicine Q Family Practice Q Gastroenterology Q Hem/Onc QHepatology Q Infectious Disease Q Internal Medicine Q Nephrology/Urology 0OB/GYN Q Pediatrics Q Other
2. In the past 12 months, how many patients have you diagnosed NoneQ 15Q 6-100 >10 Qor treated for Hepatitis C?
3. Do you generally refer patients with suspected or confirmed Yes Q No Qhepatitis C to other physicians for further evaluation an&
treatment?
4. In the past 12 months, how many patients with hepatitis C NoneQ 1-50 6-100 >10 Qhave you treated with interferon?
5. Today, are you more or less likely to treat hepatitis C with MoreQ Less Q No DifferenceQinterferon than you were 12 months ago?
6. For any of your hepatitis C patients, are there restrictions Yes Q No Q Not Sure Qplaced on the care you provide by the patient’s health care
plan or managed care company? For example, must you
obtain prior approval for diagnostic tests or before
prescribing anti-hepatitis C pharmaceuticals?
Please indicate the frequency with which you recommend the following to your patients:
Almost AlmostI counsel my Hepatitis C patients to: Always Sometimes Never
7. Not share toothbrushes or razors 0 0 0
8. Not share drinking glasses 0 0 0
9. Not hug or kiss children 0 0 0
0. Not donate blood or organs 0 0 01. Minimize alcohol consumption 0 0 012.Abstain from alcohol consumption 0 0 013, Use condoms in a monogamous sexual relationship 0 0 014. Have sexual partners checked for HCV 0 a 015. Be vaccinated against hepatitis A 0 0 016. Be vaccated against hepatitis B
. Q Q 017. Use alternative/supplemental treatments such as herbal remedies 0 0 0
Case History #1
After attempting to donate blood for the first time, a 36 year old woman was told she is positive for antibody tohepatitis C virus (HCV) and referred to you. She has no symptoms and has no history of henatitis or iaunc1ce.Examination is normal. Blood tests show normal activities of serum aminotransferases (ALT and ASt, alsoknown as SGPT and SGOT) and normal bilirubin and albumin concentrations.
For this patient, would you order the following tests?
Yes No Maybe
18. Antibody to HCV by recombinant immunoblot assay (Matrix, RIBA) Q 0 0
19. HCV Genotyping Q 0 Q
20. Qualitative PCR for HCV RNA 0 0 021. Quantitative PCR for HCV RNA 0 0 0
(Continued on back)
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If HCV infection is confirmed in this patient, would you recommend the following?
isty2
Yes
0
0
0
0
C)
No
0
0
0
0
C
Maybe
0
0
0
0
C
A 54 year old man has a history of trauma requiring blood transfusions 15 years ago. He has intermittent
symptoms of fatigue. Other than the liver being mildly tender, physical examination is normal. Blood tests show
raised serum aminotransferase activities (ALTh267, AST=1 32); normal bilirubin and albumin concentrations, and
normal prothrombin time. He is positive for anti-HCV.
For this patient, would you order the following tests?
27, Antibody to HCV by recombinant immunoblot
assay (Matrix, RIBA)
28. HCV Genotyping
29. Qualitative PCR for HCV RNA
30. Quantitative PCR for HCV RNA
If HCV infection is confirmed in this patient, would you recommend the following?
Thank you for your participation.
Piease return this anonymous survey in the envelope provided to:
State of Hawaii Department of Health,
Epidemiology Branch,
1250 Punchbowl Street, Rm 444,
Honolulu, HI 96813
22. Liver biopsy
23. Ultrasound of the abdomen
24. Monitoring by aminotransferase every 6-12 months
25. Counseling only
26. Treatment with interferon
If yes, what kind of interferon?
what dosing schedule?
Consensus a Alpha Other Q
3 - 6 million units Q 3 - 6 million units Q3x weekly daily
follow-up how often? 2x a yearQ 3-4x a year Q >5x a yearQ
Yes No Maybe
0 0 0
0 0 0
0 0 0
0 0 0
No MaybeYes
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
31 . Liver biopsy
32. Ultrasound of the abdomen
33. Monitoring by aminotransferase every 6-12 months
34. Counseling only
35. Treatment with interferon
If yes, what kind of interferon? Consensus Q Alpha Q Other Q
what dosing schedule? 3 - 6 million units Q 3 - 6 million units Q Other Q3x weekly daily
follow-up how often? 2x a yearQ 3-4x a year Q >5x a yearQ36. Treatment with interferon + ribavirin 0 0 0If yes, what treatment protocol? StandardlScheringQ ResearchQ OtherQ
follow-up how often? 2x a yearQ 3-4x a year Q >5x a yearQ
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